Video Center


The OBR Video Center Features educational videos covering a wide range of oncology specific topics.

Eric Jonasch, MD, on integrating immunotherapies into renal cell carcinoma treatment algorithms

Dr. Jonasch, MD, Professor, Department of Genitourinary Medical Oncology, Division of Cancer Medicine, The University of Texas MD Anderson Cancer Center, on how immunotherapies are being integrated into renal cell carcinoma treatment algorithms.

Published: 24 February 2017

Recent Videos: ASCO GU Conference Coverage

video

Yair Lotan, MD, regarding the role of molecular markers in high-risk bladder cancer patients

Dr. Lotan, Professor, Chief of Urologic Oncology, Holder of the Helen J. and Robert S. Strauss Professorship in Urology, UT ...

video

Yair Lotan, MD, explains how new guidelines have changed the treatment of bladder cancer

Dr. Lotan, Professor, Chief of Urologic Oncology, Holder of the Helen J. and Robert S. Strauss Professorship in Urology, UT ...

video

Yair Lotan, MD, considers the implications of the POUT study presented at ASCO GU 2018

Dr. Lotan, Professor, Chief of Urologic Oncology, Holder of the Helen J. and Robert S. Strauss Professorship in Urology, UT ...

video

Yair Lotan, MD, on how multi-modality treatment is being applied to locally advanced bladder cancer

Dr. Lotan, Professor, Chief of Urologic Oncology, Holder of the Helen J. and Robert S. Strauss Professorship in Urology, UT ...

video

Petros Grivas, MD, PhD, regarding the role of immunotherapy in metastatic bladder cancer

Dr. Grivas, Associate Professor, Medicine Clinical Director, GU Oncology, University of Washington, elaborates on the role of immunotherapy in patients ...

video

Petros Grivas, MD, PhD, on combining immunotherapy and chemotherapy in metastatic bladder cancer

Dr. Grivas, Associate Professor, Medicine Clinical Director, GU Oncology, University of Washington, offers opinion on the best way to combine ...

video

Petros Grivas, MD, PhD, considers the role of the PD-L1 biomarker in the treatment of bladder cancer

Dr. Grivas, Associate Professor, Medicine Clinical Director, GU Oncology, University of Washington, shares thoughts on the usefulness of the PD-L1 ...

video

Petros Grivas, MD, PhD, discusses molecular characterization & bladder subtyping data

Dr. Grivas, Associate Professor, Medicine Clinical Director, GU Oncology, University of Washington, explains how molecular characterization and bladder subtyping data ...

video

Petros Grivas, MD, PhD, outlines the POUT study presented at ASCO GU 2018

Dr. Grivas, Associate Professor, Medicine Clinical Director, GU Oncology, University of Washington, tells us about the POUT clinical study presented ...

video

Petros Grivas, MD, PhD, on the role of DNA repair gene mutations in metastatic urothelial carcinoma

Dr. Grivas, Associate Professor, Medicine Clinical Director, GU Oncology, University of Washington, discusses whether DNA repair gene mutations have a ...

Related Videos

video-image

Yair Lotan, MD, considers the implications of the POUT study presented at ASCO GU 2018

video-image

Yair Lotan, MD, explains how new guidelines have changed the treatment of bladder cancer

video-image

Yair Lotan, MD, regarding the role of molecular markers in high-risk bladder cancer patients

video-image

Yair Lotan, MD, on how multi-modality treatment is being applied to locally advanced bladder cancer

video-image

Petros Grivas, MD, PhD, on the role of DNA repair gene mutations in metastatic urothelial carcinoma

video-image

Petros Grivas, MD, PhD, outlines the POUT study presented at ASCO GU 2018

video-image

Petros Grivas, MD, PhD, discusses molecular characterization & bladder subtyping data

video-image

Petros Grivas, MD, PhD, considers the role of the PD-L1 biomarker in the treatment of bladder cancer

video-image

Petros Grivas, MD, PhD, on combining immunotherapy and chemotherapy in metastatic bladder cancer

video-image

Petros Grivas, MD, PhD, regarding the role of immunotherapy in metastatic bladder cancer

video-image

Daniel P. Petrylak, MD, on the role of DNA repair gene mutations in metastatic urothelial carcinoma

video-image

Daniel P. Petrylak, MD, offers opinion on the POUT study presented at ASCO GU 2018

video-image

Daniel P. Petrylak, MD, on molecular characterization & bladder subtyping in bladder cancer

video-image

Daniel P. Petrylak, MD, on immunotherapy & chemotherapy combinations in metastatic bladder cancer

video-image

Naomi B. Haas, MD, on how patient characteristics play a role in sequencing in metastatic RCC

video-image

Naomi B. Haas, MD, on how immunotherapies are being integrated into kidney cancer treatment

video-image

Naomi B. Haas, MD, explains how cabozantinib is being integrated into treatment of renal cell cancer

video-image

Daniel J. George, MD, discusses the difference in mortality in the PROSPER and SPARTAN trials

video-image

Daniel J. George, MD, regarding the conclusions from the SPARTAN study at ASCO GU 2018

video-image

Peter C. Black, MD, FACS, FRCSC, outlines the results of the POUT study presented at ASCO GU 2018

video-image

Peter C. Black, MD, FACS, FRCSC, on molecular characterization & bladder subtyping data

video-image

Peter C. Black, MD, FACS, FRCSC, regarding checkpoint blockade in non-muscle invasive bladder cancer

video-image

Nicholas J. Vogelzang, MD, on the benefit of adding docetaxel to 1st line, long-term hormone therapy

video-image

Nicholas J. Vogelzang, MD, discusses the difference in mortality in the PROSPER and SPARTAN trials

video-image

Nicholas J. Vogelzang, MD, regarding the conclusions from the SPARTAN trial at ASCO GU 2018

video-image

Nicholas J. Vogelzang, MD, outlines the results of the PROSPER study presented at ASCO GU 2018

video-image

Thomas Powles, MD, MBBS, MRCP, regarding immunotherapy & chemotherapy combinations in bladder cancer

video-image

William K. Oh, MD, on abiraterone acetate fine particle formulation

video-image

William K. Oh, MD, discusses how PET scans are changing the way we diagnose & treat prostate cancer

video-image

William K. Oh, MD, considers the impact of apalutamide on M0 CRPC patients

video-image

Christopher J. Kane MD, FACS, considers how radiotherapy should be applied after prostatectomy

video-image

Christopher J. Kane MD, FACS, regarding the use of neoadjuvant therapy in prostate cancer

video-image

Christopher J. Kane MD, FACS, on how the field of imaging is evolving

video-image

Maha Hussain, MD, FACP, FASCO, offers opinion on how to avoid over-treatment and under-treatment

video-image

Maha Hussain, MD, FACP, FASCO, considers the integration of biomarkers into treatment algorithms

video-image

Maha Hussain, MD, FACP, FASCO, regarding immunotherapy & castrate-resistant prostate cancer

video-image

Peter C. Black, MD, FACS, FRCSC, on impact of The Cancer Genome Atlas Project in bladder cancer

video-image

Mark Emberton, MD, on how we avoid under diagnosing and over diagnosing in prostate cancer

video-image

Daniel P. Petrylak, MD, regarding PD-L1 biomarkers in the treatment of bladder cancer

video-image

Daniel P. Petrylak, MD, outlines overall survival and immune responses from the STRIDE study

video-image

Daniel P. Petrylak, MD, on the Phase I data of enfortumab vedotin in mUC patients from ASCO GU 2018

video-image

Naomi B. Haas, MD, offers opinion on the optimal sequencing of agents in treatment of RCC

video-image

Naomi B. Haas, MD, considers the role of TKIs in the treatment of renal cell cancer

video-image

Naomi B. Haas, MD, on what clinical evidence can tell us about the adjuvant treatment of RCC

video-image

Daniel J. George, MD, tells us about the results of the PROSPER study presented at ASCO GU 2018

video-image

Daniel J. George, MD, on how genomics are being incorporated into prostate cancer treatment

video-image

Daniel J. George, MD, regarding toxicity concerns when using sunitinib in RCC

video-image

Daniel J. George, MD, on the effectiveness of sunitinib in the adjuvant treatment of high-risk RCC

video-image

Peter C. Black, MD, FACS, FRCSC, considers preferred checkpoint inhibitors for urothelial carcinoma

video-image

Peter C. Black, MD, FACS, FRCSC, on the usefulness of molecular markers in bladder cancer treatment

video-image

Nicholas J. Vogelzang, MD, considers genomics and systemic therapy in advanced prostate cancer

video-image

Nicholas J. Vogelzang, MD, regarding the latest trends in diagnosis of advanced prostate cancer

video-image

Nicholas J. Vogelzang, MD, on immunotherapy & prostate cancer treatment algorithms

video-image

Thomas Powles, MD, MBBS, MRCP, on the evolving landscape of metastatic bladder cancer

video-image

Thomas Powles, MD, MBBS, MRCP, considers molecular markers and muscle-invasive bladder cancer

video-image

William K. Oh, MD, on biomarkers and prostate cancer treatment algorithms

video-image

William K. Oh, MD, regarding the results of the PROSPER and SPARTAN studies at ASCO GU 2018

video-image

Christopher J. Kane MD, FACS, considers how MRI is helping diagnose and treat prostate cancer

video-image

Christopher J. Kane MD, FACS, on trends in the multimodality treatment of localized prostate cancer

video-image

Maha Hussain, MD, FACP, FASCO, on the potential impact of the PROSPER study

video-image

Maha Hussain, MD, FACP, FASCO, discusses the results of the PROSPER study at ASCO GU 2018

video-image

Mark Emberton, MD, on imaging as an effective tool for diagnosing prostate cancer

video-image

Mark Emberton, MD, elaborates on the acceptance of imaging as a diagnostic tool in prostate cancer

video-image

Mark Emberton, MD, describes how MRI has improved the diagnosis of prostate cancer

video-image

Mark Emberton, MD, offers opinion on new ways to screen for prostate cancer

video-image

Mark Emberton, MD, regarding the evolution of imaging in localized prostate cancer

video-image

Mark Emberton, MD, considers the challenges in diagnosing men with prostate cancer

video-image

Melissa Johnson, MD, discusses combinations and the treatment of lung cancer

video-image

Alan Venook, MD, considers how immunotherapy is being integrated into CRC treatment algorithms

video-image

Parameswaran Hari, MD, MRCP, MS, on promising cellular immunotherapy studies from ASH 2017

video-image

Parameswaran Hari, MD, MRCP, MS, on how the field of immunotherapy is evolving for MM patients

video-image

Sandip Patel, MD, discusses some solutions for managing toxicities associated with immunotherapies

video-image

Sandip Patel, MD, considers immunotherapy combinations and the likelihood of severe adverse events

video-image

Sandip Patel, MD, on identifying patient types likely to experience immune-related adverse events

video-image

Sandip Patel, MD, describes the prominent safety challenges with administration of immunotherapies

video-image

Sandip Patel, MD, on the role of immunotherapies when treating cancer near end of life

video-image

Practical Issues When Treating With Immunotherapy

video-image

Beyond PD-L1: In Search of Better Biomarkers

video-image

Evolving Immunotherapy Combinations

video-image

Mary Jo Fidler, MD, FASCO, comments on the outlook for immunotherapy combinations in SCLC

video-image

Mary Jo Fidler, MD, FASCO, offers opinion on integrating immunotherapies into treatment of SCLC

video-image

Jeffrey Meyerhardt, MD, on how immunotherapies are being studied in gastric & esophageal cancers

video-image

Howard Hochster, MD, explains the impact of immunotherapies on gastric GE junction cancers

video-image

Barbara Burtness, MD, discusses immunotherapies and treatment of head and neck cancers

video-image

Phil Bonomi, MD, on immunotherapy for treatment of SCLC and mesothelioma

video-image

Noa Biran, MD, shares how immunotherapies are being integrated into MM treatment algorithms

video-image

Jack West, MD, discusses possible immunotherapy combination treatments in the near future

video-image

Jack West, MD, on anti-PD-L1/PD-1 therapy in combination with chemotherapy & targeted therapies

video-image

Debu Tripathy, MD, on immunotherapies being studied for treatment of metastatic breast cancer

video-image

Mohammad Jahanzeb, MD, FACP, on immunotherapy and treatment of metastatic breast cancer

video-image

Philip Philip, MD, considers the benefits of immunotherapy in treating gastrointestinal cancer

video-image

Sundar Jagannath, MD, on immunotherapies and multiple myeloma treatment algorithms

video-image

Robert Figlin, MD, explains how checkpoint inhibitors are changing the way RCC is treated

video-image

Robert Figlin, MD, discusses sequencing when treating metastatic RCC patients

video-image

Robert Figlin, MD, on choosing the most appropriate treatment algorithm for metastatic RCC patients

video-image

Robert Figlin, MD, offers his opinion on interesting abstracts at ASCO 2017 related to RCC

video-image

Robert Figlin, MD, speculates on the changing landscape of RCC treatment